ArticleNature medicine2024

Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.

Jordi Rodón et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.